Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (273)	10/10/2005 6:58:18 PM
From: tuck	Read Replies (1) \| Respond to of 447

Thanks, Doc, I gathered from another source that DNA talked about inventory drawdown. A YMB poster listening to the call (I can't right now: PC to close to sleeping significant other) also managed to decipher the thick accent of a DNA manager who answered a Tarceva question with "penetration of Tarceva for its FIRST indication - in lung cancer, went up from 25% to 29% in one quarter!" Interesting how the scrip numbers weren't telling the short term tale, but they will tell in the long term. No happy at being down a bit, but happy to hold, and might even add at these levels. Cheers, Tuck